Bit.Bio company information, Employees & Contact Information

UK cell therapy biotech lays off 25% of staff, turns to tool development over therapeutics Fierce Biotech

Simplifying Cell Visualization in Complex Model Systems Technology Networks

bit.bio clears the way for next phase of growth Business Weekly

Venture Capital Funding Flowing into the iPSC Sector by Year BioInformant

Designer Stem Cells Power New R&D Assay Systems Genetic Engineering and Biotechnology News

Inside the British lab growing a biological computer Financial Times

You Can Now Rent a Flesh Computer Grown in a British Lab ScienceAlert

Change of Heart—Literally: Engineered Cells Flip the Script on Organ Failure SynBioBeta

Modelling human neurodegenerative diseases in research and drug discovery Nature

bit.bio Launches ioTracker Cells Range at SLAS 2025, Adding New Visualisation Functionality to Human iPSC-derived Cell Types PR Newswire UK

bit.bio raises $30 Million led by M&G Investments Cambridge Network

BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery and manufacture of regulatory T cell (Treg) based therapies Bayer

How iPSCs are revolutionizing myelination models for multiple sclerosis drug discovery? News-Medical

The End of the Beginning for Cell and Gene Therapy, Part 2 Inside Precision Medicine

Jonathan Milner’s role as interim CEO at bit.bio concludes Cambridge Independent

bit.bio Business Weekly

bit.bio's opti-ox™ Tech Gains Unprecedented Global Patent Coverage SynBioBeta

One quarter of bit.bio’s staff axed as stem cell company drops therapeutics division Cambridge Independent

Milner steps into CEO role as bit.bio unveils $30m funding Business Weekly

bit.bio Welcomes New CFO to Drive Financial Strategy and Growth SynBioBeta

Like LEGOs, bit.bio’s CNS Tool Kit Allows Brain Exploration Piece by Piece Genetic Engineering and Biotechnology News

bit.bio’s incoming interim CEO Jonathan Milner pledges ‘focus’ in role Cambridge Independent

Synthego, bit.bio Collaborate on Multiplexed Cell Engineering Platform Genetic Engineering and Biotechnology News

bit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox™ Cell Programming Technology BioSpace

bit.bio Raises in Excess of $100 Million in First Close of Series B Financing Business Wire

Bit BioBit: Joining the power of computation and biology Science | AAAS

Bit.bio launches human astrocyte product to help model brain Multiple Sclerosis News Today

Shock terminations of world-class Cambridge scientists and entrepreneurs as bit.bio ‘realigns’ directors Cambridge Independent

bit.bio raises $103 million in first close of Series B financing Drug Target Review

Kathryn Corzo's vision: Steering bit.bio's cell therapies with opti-ox drugdiscoverytrends.com

Mekonos Announces Research Collaboration With bit.bio to Advance Cell Engineering Business Wire

bit.bio, MJFF to develop human cell products for research in Parkinson’s Parkinson's News Today

bit.bio pursues global billions after winning key patent battle Business Weekly

bit.bio expands Board of Directors with the Appointment of Entrepreneurs and a Nobel Laureate Business Wire

ecoLogicStudio's Bit.Bio.Bot wants you to farm algae at home as protein source and to purify air Designboom

What’s in Vogue for SynBio’s Retooling of Nature’s Code? Genetic Engineering and Biotechnology News

Exploring Human iPSC-Derived Astrocytes for Advancing CNS Research Technology Networks

IoPPN scientists collaborate with bit.bio to develop multi-cell models of the human brain with optimised open-source protocols King's College London

bit.bio closes $30m round and Jonathan Milner takes interim CEO role with Mark Kotter now vice chairman Cambridge Independent

bit.bio and KCL to collaborate for neurodevelopmental disorders PharmaTimes

GC Therapeutics secures $65m to launch into off-the-shelf iPSC therapy space Pharmaceutical Technology

Reprogramming Stars #14: Fast-Forwarding Cellular Reprogramming— An Interview with Dr. Mark Kotter Mary Ann Liebert, Inc.

Meet The Company Democratizing Access To Human Cells Forbes

This Startup Is Making—and Programming—Human Cells WIRED

Bit.Bio.Bot exhibition shows how algae can be used as air purifiers and protein source Dezeen

bit.bio Launches New Custom Disease Model Cells Offering Technology Networks

bit.bio Expands Independent Ethics and Sustainability Board as Part of Commitment to Being a Purpose Driven Company Business Wire

How to create an iPSC-derived in vitro model to study neuroinflammation News-Medical

bit.bio named Emerging Star at European Mediscience Awards 2022 Business Wire

BitBiome Announces Manufacturing Partnership with Leading CMO to Deliver Full-Scale Biomanufacturing Capabilities SynBioBeta

Combining Coding and Biology To Engineer Human Cells Technology Networks

bit.bio unveils first Parkinson’s project with The Michael J. Fox Foundation Business Weekly

UK Startup Bags €37M to Remove Cell Therapy Manufacturing Bottleneck Labiotech.eu

ioAstrocytes - Human iPSC-Derived Astrocytes Technology Networks

BIT.BIO.BOT: a prototype dwelling and collective experiment in biotech architecture ARQA

This technology was designed to grow human cells. Now it's transforming the cultured meat industry. Massive Science

Arm founder appointed chair of MedTech bit.bio BusinessCloud

ioGABAergic Neurons – iPSC-Derived Inhibitory Neurons With >95% Purity Technology Networks

A Molecular Portrait of ALS and FTD Drug Target Review

Min Liu succeeds Yiping Li as CEO of JW BioCentury

Female leaders join bit.bio with COO ‘proud of team we’re building’ Cambridge Independent

Government publishes £2 billion vision for engineering biology to revolutionise medicine, food and environmental protection GOV.UK

Precision of bit.bio’s cells is ‘a watershed moment for biology’ Cambridge Independent

Biotech startup Bit Bio aiming to 'reprogramme' human cells recruits industry leaders business-live.co.uk

ecoLogicStudio installs prototype dwelling addressing biotech architecture at Venice Biennale World Architecture Community

bit.bio pipeline powers up with new expertise joining the SAB Cambridge Independent

Science minister bit.bio’s new labs as engineering biology gets £2bn boost Cambridge Independent

Prologis nears prelet at next Cambridge Biomedical Campus block Estates Gazette

Przemek Obloj joins bit.bio as CFO Cambridge Independent

A.P. Bio gives Jack a bit too much credit in a funny, but predictable episode AV Club

Bit Bio lease means BioMed@Babraham is full after only 12 months Cambridge Independent

bit.bio partners Charles River for new human cell era Cambridge Independent

Rejuvenating! $4m for start-up clock.bio in search for anti-ageing grail Cambridge Independent

Bit early to celebrate US Bio secure Act as Indian CRDMO players await clarity on tariffs financialexpress.com

BIT.BIO.BOT: a prototype dwelling and collective experiment in biotech architecture by ecoLogicStudio_17th International Architecture Exhibition of la Biennale di Venezia | 22 May – 21 November 2021 Archisearch

bit.bio + London Institute for Mathematical Sciences = progress on industrial-scale production of all human cells Cambridge Independent

Weslie Janeway welcomed to the board of director at cell coding company bit.bio Cambridge Independent

Healx and Bit Bio engage patients with rare diseases for public webinar Cambridge Independent

WICI Talk: Professor Sara Walker “Bio from Bit: Quantifying the Origins of Life” University of Waterloo

Dr Hon Weng Chong’s Cortical Labs, creator of DishBrain, banks $10m AFR

Meet BitBio as cell coding firm retires the Elpis Biomed name Cambridge Independent